Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Primary Progressive Multiple Sclerosis (PPMS) Clear all

Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999

View directory record Official record

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Source: ClinicalTrials.gov public record

Updated Mar 29, 2026 · Synced May 22, 2026, 4:45 AM EDT

Terminated Phase 3 Interventional Results available

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT00731692

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: FTY720, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 65 Years

Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 33
States / cities: Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more

Source: ClinicalTrials.gov public record

Updated Jun 13, 2017 · Synced May 22, 2026, 4:45 AM EDT

Recruiting Phase 1 Interventional

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

NCT06680037

View directory record Official record

Conditions: B-cell Mediated Autoimmune Disorders
Interventions: Azercabtagene zapreleucel (azer-cel); Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 22, 2026, 4:45 AM EDT

Active, not recruiting Not applicable Interventional

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

NCT03983681

View directory record Official record

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years

Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Source: ClinicalTrials.gov public record

Updated May 6, 2025 · Synced May 22, 2026, 4:45 AM EDT

Completed Phase 2 Interventional Results available

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

NCT02284568

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Placebo, Laquinimod; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 25 Years to 55 Years

Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more

Source: ClinicalTrials.gov public record

Updated Mar 9, 2022 · Synced May 22, 2026, 4:45 AM EDT

Completed No phase listed Observational

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

NCT05974852

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years

Enrollment: 732 participants
Timeline: 2023
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 22, 2026, 4:45 AM EDT

Completed Phase 3 Interventional Results available

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

NCT02688985

View directory record Official record

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Source: ClinicalTrials.gov public record

Updated Jun 3, 2024 · Synced May 22, 2026, 4:45 AM EDT

Recruiting Phase 1Phase 2 Interventional

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Kansas City, Kansas • St Louis, Missouri

Source: ClinicalTrials.gov public record

Updated Mar 18, 2026 · Synced May 22, 2026, 4:45 AM EDT

Completed No phase listed Observational

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

NCT05974839

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years

Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Source: ClinicalTrials.gov public record

Updated Sep 25, 2024 · Synced May 22, 2026, 4:45 AM EDT

Suspended Phase 1 Interventional

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

NCT06677710

View directory record Official record

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2025 · Synced May 22, 2026, 4:45 AM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

NCT03606460

View directory record Official record

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Wellesley, Massachusetts • Cleveland, Ohio + 2 more

Source: ClinicalTrials.gov public record

Updated Jun 28, 2020 · Synced May 22, 2026, 4:45 AM EDT

Completed Phase 3 Interventional

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more

Source: ClinicalTrials.gov public record

Updated Jan 6, 2026 · Synced May 22, 2026, 4:45 AM EDT

Completed Phase 1 Interventional

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289

View directory record Official record

Conditions: Primary Progressive Multiple Sclerosis
Interventions: DUOC-01; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years to 65 Years

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Source: ClinicalTrials.gov public record

Updated Jan 7, 2026 · Synced May 22, 2026, 4:45 AM EDT